Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 1:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 4,737 matching trials from the live ClinicalTrials.gov search.
Conditions
COPD, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Severe, Chronic Obstructive Pulmonary Disease Moderate
Interventions
Wellinks
Other
Lead sponsor
Convexity Scientific Inc
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia
Conditions
COPD
Interventions
Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 7 more
Conditions
Snoring, Mouth Breathing, Daytime Sleepiness, Periodontitis
Interventions
Oral appliance therapy plus scaling and root planing on left or right of mouth
Device
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Completed Not applicable Interventional Accepts healthy volunteers Results available

Breathing Interventions for Relaxation: Dosing Through Extended Exhale

NCT02870868
Conditions
Healthy Adults, Stress
Interventions
Slow breathing
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
30 Years to 60 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole MR
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Overland Park, Kansas
Conditions
Cardiac Arrest (CA)
Interventions
Precision-Controlled Ventilation with Real-Time Feedback, Standard Manual Ventilation During CPR
Device · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Pyrimethamine, Sulfamethoxazole/Trimethoprim, Sulfadoxine/Pyrimethamine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 6 more
Recruiting No phase listed Observational Accepts healthy volunteers

Timing of Opioid Administration and Postoperative Respiratory Depression.

NCT07227389
Conditions
Respiratory Complications, Opioid Induced Respiratory Depression, Postoperative Respiratory Complications
Interventions
Respiratory volume monitoring
Diagnostic Test
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide, Fluticasone Propionate/Salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 99 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
35
States / cities
Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more
Completed Phase 4 Interventional Results available

Erenumab for Idiosyncratic Facial Pain

NCT04249427
Conditions
Facial Pain, Rhinosinusitis
Interventions
Erenumab Prefilled Syringe, Placebo
Drug · Other
Lead sponsor
David Jang, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Active, not recruiting Phase 1 Interventional

Atezolizumab for Idiopathic Pulmonary Fibrosis

NCT05515627
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Atezolizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
COVID-19, Atrial Fibrillation New Onset
Interventions
ILR, PMK, ICD
Device
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Kansas City, Kansas • Austin, Texas
Conditions
Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
Interventions
REGENECYTE, Placebo
Biological
Lead sponsor
StemCyte, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami Lakes, Florida
Conditions
Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer
Interventions
LY4175408, Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
15
States / cities
Stanford, California • Orlando, Florida • Sarasota, Florida + 11 more
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
VX-814, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
22
States / cities
Birmingham, Alabama • Sacramento, California • Denver, Colorado + 19 more
Completed No phase listed Observational

Clinical Evaluation of QFlu Combo Test

NCT01506583
Conditions
Cough, Myalgia, Nasal Obstruction, Sore Throat, Headache, Fatigue, Fever
Interventions
Not listed
Lead sponsor
Cellex, Inc.
Industry
Eligibility
Not listed
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland
Conditions
COPD, COPD - Chronic Obstructive Pulmonary Disease
Interventions
Activated ROAM System with User Feedback, Sham Comparator
Device
Lead sponsor
Barron Associates, Inc.
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Critical Illness, Acute Respiratory Failure
Interventions
Olimel (5.7%E / N9E)
Drug
Lead sponsor
Clinical Evaluation Research Unit at Kingston General Hospital
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Boulder, Colorado • St Louis, Missouri • Cleveland, Ohio + 3 more
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
4,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Completed Phase 2 Interventional Results available

Effect of BIBW 2948 BS in COPD

NCT00423137
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
BIBW 2948 BS, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 1 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
87
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more
Conditions
Respiratory Failure, Infant, Persistent Fetal Circulation
Interventions
inhaled Nitric Oxide, Oxygen (>90% by hood) - standard therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Hour to 1 Week
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic, Hematopoietic Stem Cell Transplant, Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, Adult T-Cell, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, in Remission, Cancer Remission
Interventions
TRX103
Biological
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Conditions
Esophageal Atresia, Tracheoesophageal Fistula
Interventions
Transanastomotic Tube (5FR), No Transanastomotic Tube
Device · Other
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
Up to 6 Months
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 7 more